Compare IMMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMR | ACIU |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 247.6M |
| IPO Year | 1999 | 2015 |
| Metric | IMMR | ACIU |
|---|---|---|
| Price | $7.35 | $2.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $13.50 | $10.00 |
| AVG Volume (30 Days) | ★ 312.3K | 145.9K |
| Earning Date | 04-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $35,013,000.00 | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $42.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $2.10 |
| 52 Week High | $8.05 | $4.00 |
| Indicator | IMMR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 48.43 |
| Support Level | $6.30 | $2.52 |
| Resistance Level | $7.82 | $2.68 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 43.07 | 16.28 |
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.